JP2023545521A5 - - Google Patents
Info
- Publication number
- JP2023545521A5 JP2023545521A5 JP2023523084A JP2023523084A JP2023545521A5 JP 2023545521 A5 JP2023545521 A5 JP 2023545521A5 JP 2023523084 A JP2023523084 A JP 2023523084A JP 2023523084 A JP2023523084 A JP 2023523084A JP 2023545521 A5 JP2023545521 A5 JP 2023545521A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- cdr1
- seq
- acid sequences
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/120918 | 2020-10-14 | ||
| CN2020120918 | 2020-10-14 | ||
| CNPCT/CN2021/085335 | 2021-04-02 | ||
| CN2021085335 | 2021-04-02 | ||
| PCT/CN2021/123438 WO2022078357A1 (en) | 2020-10-14 | 2021-10-13 | Anti-pd-1/cd40 bispecific antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023545521A JP2023545521A (ja) | 2023-10-30 |
| JP2023545521A5 true JP2023545521A5 (cg-RX-API-DMAC7.html) | 2024-10-24 |
Family
ID=81207517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023523084A Pending JP2023545521A (ja) | 2020-10-14 | 2021-10-13 | 抗pd-1/cd40二重特異性抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230220082A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4229096A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023545521A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230092932A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116390755A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021359495A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023006989A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3197463A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302042A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023004275A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022078357A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117624372A (zh) * | 2022-08-26 | 2024-03-01 | 北京天广实生物技术股份有限公司 | 靶向cd40和pd-l1的抗体及其用途 |
| CN116023495B (zh) * | 2022-09-05 | 2023-10-03 | 上海百英生物科技股份有限公司 | 一种抗cd40纳米抗体及其制备方法与应用 |
| EP4590710A1 (en) * | 2022-09-20 | 2025-07-30 | Currus Biologics Pty Ltd | A method of rescuing exhausted immune cells |
| CN120584137A (zh) * | 2023-01-06 | 2025-09-02 | 阿帕特夫研究和发展有限公司 | 双特异性pd-l1和cd40结合分子以及其用途 |
| IL328132A (en) | 2023-11-03 | 2026-06-01 | Biontech Zhuhai Pharmaceuticals R&D Co Ltd | Anti-pd-1/cd40 bispecific antibody and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110114089A (zh) * | 2016-11-02 | 2019-08-09 | 埃派斯进有限公司 | 组合中的抗cd40抗体及其使用方法 |
| CN112105642B (zh) * | 2018-02-23 | 2023-01-31 | 祐和医药科技(北京)有限公司 | 抗pd-1抗体及其用途 |
| WO2020014974A1 (en) * | 2018-07-20 | 2020-01-23 | Eucure (Beijing) Biopharma Co., Ltd | Anti-cd40 antibodies and uses thereof |
| EP3880247A4 (en) * | 2018-11-13 | 2022-10-26 | JN Biosciences, LLC | Bispecific antibodies for activation of immune cells |
| EP4048701A4 (en) * | 2019-10-23 | 2024-05-29 | Lyvgen Biopharma Holdings Limited | Anti-cd40 binding molecules and bi-specific antibodies comprising such |
-
2021
- 2021-10-13 BR BR112023006989A patent/BR112023006989A2/pt unknown
- 2021-10-13 IL IL302042A patent/IL302042A/en unknown
- 2021-10-13 AU AU2021359495A patent/AU2021359495A1/en active Pending
- 2021-10-13 MX MX2023004275A patent/MX2023004275A/es unknown
- 2021-10-13 JP JP2023523084A patent/JP2023545521A/ja active Pending
- 2021-10-13 CA CA3197463A patent/CA3197463A1/en active Pending
- 2021-10-13 CN CN202180069673.0A patent/CN116390755A/zh active Pending
- 2021-10-13 EP EP21879400.6A patent/EP4229096A4/en active Pending
- 2021-10-13 WO PCT/CN2021/123438 patent/WO2022078357A1/en not_active Ceased
- 2021-10-13 KR KR1020237014700A patent/KR20230092932A/ko active Pending
-
2023
- 2023-01-05 US US18/150,428 patent/US20230220082A1/en active Pending
-
2025
- 2025-04-17 US US19/182,143 patent/US20260234260A1/en active Pending